How Ageing Affects Older People Living With Type 1 Diabetes
Studies how people with type 1 diabetes age and stay well.
Key facts
- Who runs it
- Helsinki University Central Hospital
- Where
- Helsinki, FinlandSee the site
- Trial code
- Registry title
- FinnDiane LifeOne Study - Impact of Ageing on People With Type 1 Diabetes
- Status
- Enrolling by invitation
- People taking part
- 400 people, planned
- Started
- 29 Jan 2024
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 2 groups
- Record updated
- 24 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with type 1 diabetes who are over 65 and already take part in the Finnish Diabetic Nephropathy Study. It looks at how they age.
- Age
- Over 65 years (minimum age 65 Years)
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes. No stage is given.
Main reasons for not taking part
- Age below 65 years
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Participants of the Finnish Diabetic Nephropathy Study
- Type 1 diabetes
- With age above 65 years
- Informed consent provided
Who cannot take part
- Age below 65 years
Where in Finland
- HUS Helsinki University HospitalHelsinki, FinlandNo longer taking part
About the trial
What the trial wants to find out
Healthy aging refers to functional ability that enables well-being in older individuals. The focus thus shifts from chronological age to functional capacity and the individual's own experience of well-being. Type 1 diabetes is a chronic condition characterized by elevated blood glucose levels, which increases the risk of cardiovascular diseases and premature death. However, the life expectancy of individuals with type 1 diabetes has significantly improved due to advances in diabetes care.
Read full original descriptionShow less
There is limited research on aging with type 1 diabetes, and this study is at the forefront of addressing this gap by examining aging-and especially healthy aging-in type 1 diabetes from multiple perspectives. The goals are to investigate how individuals with type 1 diabetes age and what their functional capacity is compared to individuals without insulin-treated diabetes. The other aim is to identify factors in midlife that predict healthy aging in people with type 1 diabetes.
The 2 groups in the trial
- Type 1 diabetes
Participants of the Finnish Diabetic Nephropathy Study, age above 65 years.
- Controls
Age above 65 years, no diabetes with insulin therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- FinnDiane LifeOne Study - Impact of Ageing on People With Type 1 Diabetes
- Plain-language title
- How Ageing Affects Older People Living With Type 1 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Publications
- Record updated
- 24 December 2025